Advertisement
Screener

Denali Therapeutics Inc. (DNLI) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Denali Therapeutics Inc. Cash Flow Breakdown

Cash flow breakdown shows where Denali Therapeutics Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $412.60M went out.
  • Fiscal year ended 2025-12-31: from investing, $255.28M came in.
  • Fiscal year ended 2025-12-31: from financing, $189.22M came in.
  • Fiscal year ended 2025-12-31: change in cash, $31.90M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingNew shares soldNot split outChange in cash
2025-12-31-$412.60M$255.28M$189.22M*$31.90M
2024-12-31-$347.69M-$88.76M$0.00$484.30M*$47.85M
2023-12-31-$357.99M$249.31M$0.00$17.82M*-$90.86M
2022-12-31-$244.72M-$141.39M$296.21M$14.46M*-$75.43M
2021-12-31-$211.39M-$21.63M$0.00$19.35M*-$213.67M
2020-12-31$416.15M-$623.21M$193.95M$440.80M*$427.69M
2019-12-31-$151.58M$147.71M$0.00$6.19M*$2.33M
2018-12-31$50.12M-$287.42M$0.00$97.02M*-$140.29M
2017-12-31-$76.64M-$41.17M$265.62M$30.70M*$178.52M
2016-12-31-$71.91M-$219.00M$0.00$300.48M*$9.56M

Each quarter (3 month)

Quarter endRunning the businessFrom investingNew shares soldNot split outChange in cash
2026-06-30-$97.00M*-$104.08M*$0.00*$14.98M*
2026-03-31-$131.20M$94.46M$12.37M$206.68M*$182.30M
2025-12-31-$98.54M*$20.77M*$192.13M*
2025-09-30-$107.30M*$57.83M*$0.00*-$778.00K*
2025-06-30-$75.30M*$157.94M*$0.00*$1.62M*
2025-03-31-$131.47M$18.75M$0.00-$3.76M*-$116.48M
2024-12-31-$83.72M*$172.21M*-$499.25M*$495.08M*
2024-09-30-$59.14M*$93.66M*$0.00*-$18.56M*
2024-06-30-$91.22M*$98.57M*$0.00*$6.76M*
2024-03-31-$113.62M-$453.19M$499.25M$1.02M*-$66.53M
2023-12-31-$98.66M*$73.05M*$0.00*$4.71M*
2023-09-30-$87.36M*$100.91M*$0.00*$2.49M*
2023-06-30-$113.17M*$168.07M*$0.00*$9.02M*
2023-03-31-$58.80M-$92.72M$0.00$1.60M*-$149.91M
2022-12-31-$72.66M*-$127.56M*$299.65M*
2022-09-30-$57.05M*$15.42M*$5.15M*
2022-06-30-$42.90M*$88.63M*$4.40M*
2022-03-31-$72.11M-$117.88M$1.46M*-$188.52M
2021-12-31-$65.49M*-$40.75M*$0.00*$5.17M*
2021-09-30-$41.43M*-$53.01M*$0.00*$3.31M*
2021-06-30-$54.22M*$97.54M*$0.00*$7.04M*
2021-03-31-$50.24M-$25.41M$0.00$3.82M*-$71.82M
2020-12-31$513.91M*-$367.34M*$0.00*$9.52M*
2020-09-30$86.00K*-$212.12M*$0.00*$425.90M*
2020-06-30-$43.36M*-$30.41M*$0.00*$3.42M*
2020-03-31-$54.49M-$13.33M$193.95M$1.97M*$128.09M
2019-12-31-$47.64M*$42.38M*$0.00*$2.03M*
2019-09-30-$30.43M*$49.49M*$0.00*$679.00K*
2019-06-30-$43.17M*$63.88M*$0.00*$2.57M*
2019-03-31-$30.32M-$8.05M$0.00$908.00K*-$37.46M
2018-12-31$93.19M*-$61.40M*-$94.41M*$96.10M*
2018-09-30-$34.82M*$44.73M*$0.00*$658.00K*
2018-06-30-$41.82M*$30.53M*$0.00*$1.43M*
2018-03-31$33.58M-$301.27M$94.41M-$1.17M*-$174.46M
2017-12-31-$18.34M*-$95.15M*$265.62M*$29.97M*
2017-09-30$16.53M*
2017-06-30-$17.57M*$22.07M*
2017-03-31-$18.81M$15.38M$324.00K-$3.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43